Prophylactic systemic low-dose pirfenidone attenuates intrauterine adhesion by inhibiting the TGF-β1/Smad3 pathway
- 21 April 2026
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (6) , 168272
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81971335)
This publication has 42 references indexed in Scilit:
- Systemic low-dose anti-fibrotic treatment attenuates ovarian aging in the mouseGeroScience, 2024
- Pirfenidone use in fibrotic diseases: What do we know so far?Immunity, Inflammation and Disease, 2024
- Intrauterine interventions options for preventing recurrence after hysteroscopic adhesiolysis: a systematic review and network meta-analysis of randomized controlled trialsArchives of Gynecology and Obstetrics, 2024
- Histological study of telocytes in mice intrauterine adhesion model and their positive effect on mesenchymal stem cells in vitroCell Biology International, 2024
- Myofibroblast Markers and Microscopy Detection Methods in Cell Culture and Histology2021
- Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPKHepatology Communications, 2020
- Reactive oxygen species and fibrosis: further evidence of a significant liaisonCell and tissue research, 2016
- Extracellular matrix structureAdvanced Drug Delivery Reviews, 2016
- Analysis of Cell Proliferation and Homeostasis Using EdU Labeling2016
- Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imagingHistochemistry and Cell Biology, 2015